SCHEMBL4911071

SCHEMBL4911071

CCOC(=O)c1ccc(NC(=O)Nc2ccc(CC(=O)O)cc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.68
MEN1 O00255 5/20 0.68
MAPT P10636 4/20 0.68
TRPV1 Q8NER1 2/20 0.68
CASP3 P42574 1/20 0.68
SENP7 Q9BQF6 1/20 0.68
NAMPT P43490 2/20 0.64
KDM4E B2RXH2 1/20 0.61
POLB P06746 1/20 0.61
GAA P10253 3/20 0.60
L3MBTL1 Q9Y468 2/20 0.60
SMN1; SMN2 Q16637 5/20 0.59
NPC1 O15118 3/20 0.59
RAB9A P51151 3/20 0.59
CA12 O43570 1/20 0.59
CA1 P00915 1/20 0.59
CA2 P00918 1/20 0.59
CA9 Q16790 1/20 0.59
ALDH1A1 P00352 2/20 0.58
TSHR P16473 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4920477 0.89 MAPT (0.68) KMT2AMEN1MAPTTRPV1CASP3
SCHEMBL4112088 0.88 KMT2A (0.75) KMT2AMEN1MAPTTRPV1CASP3
SCHEMBL481332 0.88 CA1 (0.61) KMT2AMEN1MAPTNAMPTGAA
Hydrochloric Acid SCHEMBL10669311 0.86 SMN1; SMN2 (0.59) KMT2AMEN1MAPTNAMPTGAA
SCHEMBL4104395 0.85 KMT2A (0.71) KMT2AMEN1MAPTTRPV1CASP3
SCHEMBL4922844 0.85 MAPT (0.75) KMT2AMEN1MAPTTRPV1CASP3
SCHEMBL1019967 0.85 SMN1; SMN2 (0.78) KMT2AMEN1MAPTTRPV1CASP3
SCHEMBL5187464 0.84 MAOA (0.70) KMT2AMEN1MAPTTRPV1CASP3
SCHEMBL4122842 0.84 KMT2A (0.69) KMT2AMEN1MAPTTRPV1CASP3
SCHEMBL4113307 0.83 MAPT (0.77) KMT2AMEN1MAPTTRPV1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP claimed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP disclosed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R KMT2A 1905/4885MEN1 4843/4885MAPT 4151/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R KMT2A 1905/4885MEN1 4843/4885MAPT 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.